Benjamin L Deck1, Jacqueline Rick1, Sharon X Xie2, Alice Chen-Plotkin1, John E Duda1,3, James F Morley1,3, Lana M Chahine1, Nabila Dahodwala1, John Q Trojanowski4, Daniel Weintraub1,5,3. 1. Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2. Department of Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3. Parkinson's Disease Research, Education and Clinical Center (PADRECC), Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA. 4. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND: The relationship between statins and cognition in Parkinson's disease (PD) is poorly understood. OBJECTIVES: Analyses were performed to determine associations between statin use and cross-sectional and longitudinal cognitive performance in PD. METHODS: Neuropsychological tests, medication logs, and ratings of functional abilities were collected from 313 PD participants longitudinally. RESULTS: At baseline, statin users (SU; N = 129) were older, more likely male, and had shorter PD duration than non-statin users (NSU; N = 184). In Cross-sectional analysis, SU performed better on global cognition, Trails B, semantic fluency, and phonemic fluency tasks. Rate of long-term global cognitive (Dementia Rating Scale-2 and MoCA) decline was significantly less in SU.
BACKGROUND: The relationship between statins and cognition in Parkinson's disease (PD) is poorly understood. OBJECTIVES: Analyses were performed to determine associations between statin use and cross-sectional and longitudinal cognitive performance in PD. METHODS: Neuropsychological tests, medication logs, and ratings of functional abilities were collected from 313 PDparticipants longitudinally. RESULTS: At baseline, statin users (SU; N = 129) were older, more likely male, and had shorter PD duration than non-statin users (NSU; N = 184). In Cross-sectional analysis, SU performed better on global cognition, Trails B, semantic fluency, and phonemic fluency tasks. Rate of long-term global cognitive (Dementia Rating Scale-2 and MoCA) decline was significantly less in SU.
Authors: Matthew F Muldoon; Christopher M Ryan; Susan M Sereika; Janine D Flory; Stephen B Manuck Journal: Am J Med Date: 2004-12-01 Impact factor: 4.965
Authors: Guodong Liu; Nicholas W Sterling; Lan Kong; Mechelle M Lewis; Richard B Mailman; Honglei Chen; Douglas Leslie; Xuemei Huang Journal: Mov Disord Date: 2017-04-03 Impact factor: 10.338
Authors: Stella Trompet; Peter van Vliet; Anton J M de Craen; Jelle Jolles; Brendan M Buckley; Michael B Murphy; Ian Ford; Peter W Macfarlane; Naveed Sattar; Chris J Packard; David J Stott; Jim Shepherd; Eduard L E M Bollen; Gerard J Blauw; J Wouter Jukema; Rudi G J Westendorp Journal: J Neurol Date: 2009-08-04 Impact factor: 4.849